*Mycobacterium tuberculosis*, which belongs to *Mycobacterium tuberculosis* Complex (MTC) together with *M. bovis*, *M. bovis* BCG, *M. africanun*, *M. microti*, *M.canettii* and *M. pinnipedii*, is the most common etiological agent of human tuberculosis (TB). However *M*. *bovis* may also be a relevant human pathogen in countries with high prevalence of bovine TB ([@B11]). Immuno-suppressing diseases, especially caused by Human Immunodeficiency Virus (HIV), is a risk factor for the development of human TB by *M. bovis* ([@B12]; [@B03]). Since *M. bovis*-caused human TB is clinically, pathologically and radiologically undistinguishable from *M. tuberculosis*-caused TB ([@B04]), the fast differentiation of the two species has a high epidemiologic importance ([@B08]). Among molecular methods for detecting species belonging to the MTC, several markers have been employed*.* The *IS6110* is highly used since this marker is found in several copies in the MTC genome ([@B06]; [@B10]). The *pncA* gene, which encodes the pyrazinamidase enzyme (PZAase) that converts the pro-drug pyrazinamide (PZA) to pyrazinoic acid (POA), has a single point mutation at nucleotide 169C \> G (appears to be unique to *M. bovis*) is one of the markers that is commonly used to distinguish *M. bovis* from others MTC species ([@B05]; [@B07]). In the current study we evaluated a rapid test to differentiate *M. bovis* from other MTC species by one step amplification based on simultaneous detection of *pncA* 169C \> G change in *M. bovis* and the *IS6110* present in MTC species. DNA from *M. tuberculosis* H~37~Rv (ATCC 27294), *M. bovis* AN5, *M. avium* (Central Laboratory - LACEN/PR), *M. smegmatis* (LACEN/PR), *M. kansasii* (LACEN/PR), *M. fortuitum* (LACEN/PR), *M. szulgai* (LACEN/PR), *M. massilienses* (LACEN/PR), *M. abcessus* (LACEN/PR), *M. chelonae* (LACEN/PR) reference strains, one *M. bovis* BCG, 17 *M. bovis*, isolated from bovine lymph nodes and indentified by biochemical and molecular methods in a previous work ([@B02]), 30 *M. tuberculosis* clinical isolates indentified by biochemical and molecular methods in a previous work ([@B09]) were used. All *M. bovis* clinical isolates were previously characterized by spoligotyping (data not shown) and all *M. tuberculosis* by spoligotyping and MIRU ([@B09]). Amplification was carried out with specific primers for *M. tuberculosis* complex TB1 (5′-CCTGCGAGCGTAGGCGTCGG-3′) and TB2 (5′-CTCGTCCAGCGCCGCTTCGG-3′) ([@B06]) which amplify a fragment of 123 base pairs (bp) of the *IS6110* sequence and with specific primers for *M. bovis pncA*TB-1.2 (5′-ATGCGGGCGT TGATCATCGTC-3′) and *pncA*MB-2 (5′-CGGTGTGC CGGAGAAGCCG-3′) ([@B05]; [@B01]) which amplify a fragment of 186 bp of *pncA* gene. DNA extracts (1 μL) from all mycobacterial reference strains and clinical isolates, were amplified by multiplex-PCR using 24 μL reaction mixture containing 0.2 pmol/μL TB1 and TB2 primers (Invitrogen - Integrated DNA Technologies, Inc. Coralville, USA), 0.4 pmol/μL *pncA*TB-1.2 and *pncA*MB-2 primers (Invitrogen - Integrated DNA Technologies, Inc. Coralville, USA) and PCR Master Mix (Promega Corporation, Madison, Wisconsin, USA), according to manufacturer's instructions. Amplification was carried out in a Perkin-Elmer Gene Amp PCR System 2400 thermalcycler (Waltham, Massachusetts, USA) with an initial cycle of 5 min at 94 °C; 35 cycles of 1 min at 94 °C, 1 min at 68 °C, 1 min at 72 °C and a final extension at 72 °C for 10 min. *M. tuberculosis* H~37~Rv (1 ng) and *M. bovis* (1 ng) as positive and water as negative controls were included in all assays. PCR products were separated by electrophoresis on 2% agarose gel (Biotools/M&B Laboratories, S. A., Uniscience do Brasil, São Paulo, Brazil) at 100 V for 1 h in TBE. Gel were stained with ethidium bromide 0.5 μg/μL, visualized under an ultraviolet light Macrovue (Pharmacia Bioscience, Upsala, Sweden), and photodocumented digitally by Power Shot S215 (Cannon, NY, USA). A 100 bp DNA standard (Invitrogen Life Technologies, São Paulo, Brazil) was used as a DNA size marker.

The multiplex-PCR showed to be specific to differentiate *M. bovis* from other MTC species by amplification of two DNA fragments sized 123 and 186 bp and a 123 bp DNA fragment respectively. No PCR product of specific sizes to *M. tuberculosis* and *M. bovis* were observed in amplification of DNA from nontuberculous mycobacteria reference strains except for *M. avium* that showed a DNA fragment sized more than 300 bp ([Figure 1](#f01){ref-type="fig"}). Also, all *M. tuberculosis* and *M. bovis* clinical isolates (confirmed by spoligotyping) showed a single (123 bp) and two (123 and 186 pb) DNA fragments respectively, by multiplex-PCR.
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The multiplex-PCR combining TB1/TB2 ([@B06]) and *pncA*TB-1.2/*pncA*MB-2 ([@B05]) primers, proposed in this study, could not differentiate among the six species of MTC, but it showed to be specific in differentiating *M. bovis* from the others. Exception was for *M. bovis* BCG, which could not be differentiated from wild *M. bovis* (clinical isolates), once the first one tested has the 169C \> G mutation too.

The correct differentiation of *M. bovis* triggers to an appropriate therapy, knowledge on TB epidemiology and control of bovine infection ([@B05]; [@B01]; [@B04]). In fact, the proposed multiplex-PCR seems to be a very useful tool for complementation in differentiating *M. bovis* from others MTC species, which are slow-growing mycobacteria, where a small number of bacilli in cultures hinder identification by biochemical tests. Additionally, biochemical identification methods are not able to provide satisfactory results and the multiplex-PCR also has the advantage of being a fast method with results provided in one day. As consequence, a specific, fast and low cost diagnosis method is highly relevant to differentiate *M. bovis* isolates from the *M. tuberculosis* complex ([@B01]).

The multiplex-PCR showed to be an important tool for differentiation of *M. bovis* from *M. tuberculosis* cultured isolates tested. Hopefully, the proposed multiplex-PCR should be tested with the other species from the MTC to set up its potential in differentiating them as the multiplex-PCR proposed by [@B13]. The multiplex-PCR added of a internal control should also be studied in clinical specimens as additional diagnostic tool mainly in regions where bovine and human TB coexist for the monitoring infection by *M. bovis* in human beings.
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